Catabasis Pharmaceuticals, Inc. (CATB) financial statements (2021 and earlier)

Company profile

Business Address 100 HIGH STREET
BOSTON, MA 02110
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

9/30/2020
TTM
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including: 3638163963
Cash and cash equivalents 1015162463
Short-term investments 2622 15 
Other undisclosed cash, cash equivalents, and short-term investments (0)0   
Other undisclosed current assets 31111
Total current assets: 3939174064
Noncurrent Assets
Operating lease, right-of-use asset 2
Property, plant and equipment  0011
Other noncurrent assets 00  0
Other undisclosed noncurrent assets  0000
Total noncurrent assets: 30011
TOTAL ASSETS: 4239184064
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities 44355
Accounts payable 11111
Accrued liabilities 33243
Debt 1 233
Other liabilities   0  
Total current liabilities: 54688
Noncurrent Liabilities
Long-term debt and lease obligation 1    
Operating lease, liability 1
Liabilities, other than long-term debt  0000
Deferred revenue and credits000
Deferred rent credit  0
Other liabilities  0 00
Other undisclosed noncurrent liabilities    26
Total noncurrent liabilities: 10036
Total liabilities: 6461114
Stockholders' equity
Stockholders' equity attributable to parent 3635122950
Common stock 00000
Additional paid in capital 259232183173158
Accumulated other comprehensive loss  (0) (0) 
Accumulated deficit (224)(197)(171)(144)(108)
Total stockholders' equity: 3635122950
TOTAL LIABILITIES AND EQUITY: 4239184064

Income statement (P&L) ($ in millions)

9/30/2020
TTM
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Revenue, net0  
Sublease income 1
Gross profit: 1 1  
Operating expenses (27)(26)(28)(36)(32)
Other undisclosed operating loss (1)    
Operating loss: (27)(26)(27)(36)(32)
Nonoperating income (expense) 11(0)(1)(1)
Investment income, nonoperating 1000 
Other nonoperating income (expense) (0)0000
Interest and debt expense  (0)(0)(1)(1)
Loss before gain (loss) on sale of properties: (26)(26)(28)(37)(34)
Other undisclosed net income  00  
Net loss: (26)(26)(27)(37)(34)
Other undisclosed net income attributable to parent    11
Net loss available to common stockholders, diluted: (26)(26)(27)(36)(33)

Comprehensive Income ($ in millions)

9/30/2020
TTM
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Net loss: (26)(26)(27)(37)(34)
Comprehensive loss: (26)(26)(27)(37)(34)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent 0(0)01 
Comprehensive loss, net of tax, attributable to parent: (26)(26)(27)(36)(34)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: